| Hollyn Mccarty, | |
|
3920 St Francis Way Ste 100, Lafayette, IN 47905-4917 | |
| (765) 428-5990 | |
| Not Available |
| Full Name | Hollyn Mccarty |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 7 Years |
| Location | 3920 St Francis Way Ste 100, Lafayette, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083146187 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 01085424A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Franciscan Health Lafayette | Lafayette, IN | Hospital |
| Franciscan Health Rensselaer, Inc | Rensselaer, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Franciscan Physician Network | 3072790682 | 989 |
| Woman's Healthcare Associates Pc | 4789664202 | 4 |
News Archive
Avicena Group has announced day that it has filed a composition of matter patent application with the United States Patent and Trademark Office (USPTO) to cover potential treatments for Huntington's disease, a fatal neurodegenerative disease.
Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced four key belinostat data presentations at the 52nd Annual Meeting of the American Society of Hematology (ASH), being held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.
In a first-of-its-kind study, University of California San Diego School of Medicine researchers report that a blood sample, or liquid biopsy, can reveal which patients will respond to checkpoint inhibitor-based immunotherapies.
bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company's CancerTYPE ID® and Breast Cancer Index® molecular oncology tests. Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in Chicago.
› Verified 2 days ago
| Entity Name | Woman's Healthcare Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265455588 PECOS PAC ID: 4789664202 Enrollment ID: O20040723000741 |
News Archive
Avicena Group has announced day that it has filed a composition of matter patent application with the United States Patent and Trademark Office (USPTO) to cover potential treatments for Huntington's disease, a fatal neurodegenerative disease.
Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced four key belinostat data presentations at the 52nd Annual Meeting of the American Society of Hematology (ASH), being held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.
In a first-of-its-kind study, University of California San Diego School of Medicine researchers report that a blood sample, or liquid biopsy, can reveal which patients will respond to checkpoint inhibitor-based immunotherapies.
bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company's CancerTYPE ID® and Breast Cancer Index® molecular oncology tests. Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in Chicago.
› Verified 2 days ago
| Entity Name | Franciscan Physician Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225327984 PECOS PAC ID: 3072790682 Enrollment ID: O20110608000486 |
News Archive
Avicena Group has announced day that it has filed a composition of matter patent application with the United States Patent and Trademark Office (USPTO) to cover potential treatments for Huntington's disease, a fatal neurodegenerative disease.
Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced four key belinostat data presentations at the 52nd Annual Meeting of the American Society of Hematology (ASH), being held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.
In a first-of-its-kind study, University of California San Diego School of Medicine researchers report that a blood sample, or liquid biopsy, can reveal which patients will respond to checkpoint inhibitor-based immunotherapies.
bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company's CancerTYPE ID® and Breast Cancer Index® molecular oncology tests. Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in Chicago.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hollyn Mccarty, Po Box 781076, Detroit, MI 48278-1076 Ph: (317) 528-4800 | Hollyn Mccarty, 3920 St Francis Way Ste 100, Lafayette, IN 47905-4917 Ph: (765) 428-5990 |
News Archive
Avicena Group has announced day that it has filed a composition of matter patent application with the United States Patent and Trademark Office (USPTO) to cover potential treatments for Huntington's disease, a fatal neurodegenerative disease.
Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced four key belinostat data presentations at the 52nd Annual Meeting of the American Society of Hematology (ASH), being held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.
In a first-of-its-kind study, University of California San Diego School of Medicine researchers report that a blood sample, or liquid biopsy, can reveal which patients will respond to checkpoint inhibitor-based immunotherapies.
bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company's CancerTYPE ID® and Breast Cancer Index® molecular oncology tests. Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in Chicago.
› Verified 2 days ago
Brittany Sherron, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3920 St Francis Way Ste 100, Lafayette, IN 47905 Phone: 765-428-5990 | |
Karen T Regan, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 5177 Mccarty Ln, Lafayette, IN 47905 Phone: 765-448-8000 | |
Mr. Charles Jeffrey Myers, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 5177 Mccarty Ln, Lafayette, IN 47905 Phone: 765-738-6300 Fax: 765-838-6302 | |
Dr. Rearabiloe Sebata, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 5177 Mccarty Ln, Lafayette, IN 47905 Phone: 765-448-8000 Fax: 765-838-6302 | |
Dr. Erin K Ramirez, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3920 St Francis Way Ste 110, Lafayette, IN 47905 Phone: 765-428-5800 Fax: 765-428-5802 | |
Dr. Alisha Rockette, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 5165 Mccarty Ln, Lafayette, IN 47905 Phone: 765-448-8100 |